Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205289224> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W3205289224 endingPage "148" @default.
- W3205289224 startingPage "143" @default.
- W3205289224 abstract "Everolimus with exemestane (EVE+EXE) was FDA-approved to treat metastatic hormone receptor-positive breast cancer (mHRBC) based on BOLERO-2. However, none of those patients received prior CDK4/6 inhibitors. The purpose of this study is to evaluate the efficacy of EVE+EXE in mHRBC after CDK4/6 inhibitors.A retrospective review of patients ≥18 years old with mHRBC treated with EVE+EXE, for ≥30 days, at our institution from January 1, 2012, to April 1, 2020 was conducted. Primary objective was to compare progression free survival (PFS) for EVE+EXE between patients with and without prior exposure to CDK4/6 inhibitors. Secondary outcomes included overall survival and safety.192 patients were included in the study (n = 79, prior CDK4/6 inhibitor use; n = 113, no prior CDK4/6 inhibitor use). Baseline patient characteristics were similar between groups. Greater number of prior therapies before EVE+EXE use increased risk of disease progression (P = .017). Patients with prior CDK4/6 inhibitor use had a lower median PFS of 3.8 months (95% CI: 3.4-4.7) vs. 5.4 months (95% CI: 3.9-6.2) for patients without prior CDK4/6 inhibitor use, with a HR for progression of 1.46 (95% CI: 1.08 to 1.97, P = .013). Overall survival between groups was not significantly different.Patients who received a prior CDK4/6 inhibitor had a lower median PFS benefit from EVE+EXE compared to those who did not, without differences in overall survival. Although PFS is expected to decrease with subsequent lines of therapy, it is reasonable to use EVE+EXE after CDK4/6 inhibitors in selected patients, recognizing that additional benefit is modest." @default.
- W3205289224 created "2021-10-25" @default.
- W3205289224 creator A5000473164 @default.
- W3205289224 creator A5004756333 @default.
- W3205289224 creator A5024618610 @default.
- W3205289224 creator A5029484872 @default.
- W3205289224 creator A5030476275 @default.
- W3205289224 creator A5039835439 @default.
- W3205289224 creator A5056415899 @default.
- W3205289224 creator A5071015335 @default.
- W3205289224 creator A5088914288 @default.
- W3205289224 date "2022-02-01" @default.
- W3205289224 modified "2023-10-01" @default.
- W3205289224 title "Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors" @default.
- W3205289224 cites W2151082560 @default.
- W3205289224 cites W2167188058 @default.
- W3205289224 cites W2896846857 @default.
- W3205289224 cites W2948069739 @default.
- W3205289224 cites W2976415870 @default.
- W3205289224 cites W3110070773 @default.
- W3205289224 cites W3133509869 @default.
- W3205289224 doi "https://doi.org/10.1016/j.clbc.2021.10.002" @default.
- W3205289224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34740541" @default.
- W3205289224 hasPublicationYear "2022" @default.
- W3205289224 type Work @default.
- W3205289224 sameAs 3205289224 @default.
- W3205289224 citedByCount "10" @default.
- W3205289224 countsByYear W32052892242022 @default.
- W3205289224 countsByYear W32052892242023 @default.
- W3205289224 crossrefType "journal-article" @default.
- W3205289224 hasAuthorship W3205289224A5000473164 @default.
- W3205289224 hasAuthorship W3205289224A5004756333 @default.
- W3205289224 hasAuthorship W3205289224A5024618610 @default.
- W3205289224 hasAuthorship W3205289224A5029484872 @default.
- W3205289224 hasAuthorship W3205289224A5030476275 @default.
- W3205289224 hasAuthorship W3205289224A5039835439 @default.
- W3205289224 hasAuthorship W3205289224A5056415899 @default.
- W3205289224 hasAuthorship W3205289224A5071015335 @default.
- W3205289224 hasAuthorship W3205289224A5088914288 @default.
- W3205289224 hasConcept C121608353 @default.
- W3205289224 hasConcept C126322002 @default.
- W3205289224 hasConcept C141071460 @default.
- W3205289224 hasConcept C143998085 @default.
- W3205289224 hasConcept C167135981 @default.
- W3205289224 hasConcept C2775860665 @default.
- W3205289224 hasConcept C2775930923 @default.
- W3205289224 hasConcept C2776166826 @default.
- W3205289224 hasConcept C2778504769 @default.
- W3205289224 hasConcept C2779699572 @default.
- W3205289224 hasConcept C2779744173 @default.
- W3205289224 hasConcept C2780739268 @default.
- W3205289224 hasConcept C3019894029 @default.
- W3205289224 hasConcept C530470458 @default.
- W3205289224 hasConcept C71924100 @default.
- W3205289224 hasConceptScore W3205289224C121608353 @default.
- W3205289224 hasConceptScore W3205289224C126322002 @default.
- W3205289224 hasConceptScore W3205289224C141071460 @default.
- W3205289224 hasConceptScore W3205289224C143998085 @default.
- W3205289224 hasConceptScore W3205289224C167135981 @default.
- W3205289224 hasConceptScore W3205289224C2775860665 @default.
- W3205289224 hasConceptScore W3205289224C2775930923 @default.
- W3205289224 hasConceptScore W3205289224C2776166826 @default.
- W3205289224 hasConceptScore W3205289224C2778504769 @default.
- W3205289224 hasConceptScore W3205289224C2779699572 @default.
- W3205289224 hasConceptScore W3205289224C2779744173 @default.
- W3205289224 hasConceptScore W3205289224C2780739268 @default.
- W3205289224 hasConceptScore W3205289224C3019894029 @default.
- W3205289224 hasConceptScore W3205289224C530470458 @default.
- W3205289224 hasConceptScore W3205289224C71924100 @default.
- W3205289224 hasIssue "2" @default.
- W3205289224 hasLocation W32052892241 @default.
- W3205289224 hasLocation W32052892242 @default.
- W3205289224 hasOpenAccess W3205289224 @default.
- W3205289224 hasPrimaryLocation W32052892241 @default.
- W3205289224 hasRelatedWork W1901834169 @default.
- W3205289224 hasRelatedWork W2762467781 @default.
- W3205289224 hasRelatedWork W2791988073 @default.
- W3205289224 hasRelatedWork W2806908740 @default.
- W3205289224 hasRelatedWork W2887416718 @default.
- W3205289224 hasRelatedWork W2947082576 @default.
- W3205289224 hasRelatedWork W3112825892 @default.
- W3205289224 hasRelatedWork W3203690439 @default.
- W3205289224 hasRelatedWork W3205289224 @default.
- W3205289224 hasRelatedWork W4382982228 @default.
- W3205289224 hasVolume "22" @default.
- W3205289224 isParatext "false" @default.
- W3205289224 isRetracted "false" @default.
- W3205289224 magId "3205289224" @default.
- W3205289224 workType "article" @default.